These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 33965134)

  • 1. Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.
    Kow CS; Hasan SS
    Chest; 2021 May; 159(5):2108-2109. PubMed ID: 33965134
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab prescribing criteria for COVID-19 patients.
    Al-Qaaneh AM; Al-Ghamdi FH
    Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.
    González-Castro A; Cuenca Fito E; Fernandez A; Escudero Acha P; Rodríguez Borregán JC; Peñasco Y
    Med Intensiva (Engl Ed); 2022 May; 46(5):285-287. PubMed ID: 35256321
    [No Abstract]   [Full Text] [Related]  

  • 5. Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.
    Chen YW; Liao HT
    Intern Med J; 2021 Sep; 51(9):1543-1544. PubMed ID: 34541767
    [No Abstract]   [Full Text] [Related]  

  • 6. Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.
    Mombrun M; Valette X
    Chest; 2021 May; 159(5):2115-2116. PubMed ID: 33965141
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
    Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
    Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
    [No Abstract]   [Full Text] [Related]  

  • 8. Feasibility of tocilizumab in ICU patients with COVID-19.
    Issa N; Dumery M; Guisset O; Mourissoux G; Bonnet F; Camou F
    J Med Virol; 2021 Jan; 93(1):46-47. PubMed ID: 32484915
    [No Abstract]   [Full Text] [Related]  

  • 9. Remdesivir and tocilizumab: Mix or match.
    Akinosoglou K; Velissaris D; Ziazias D; Davoulos C; Tousis A; Tsiotsios K; Kalogeropoulou C; Spyridonidis A; Marangos M; Fligkou F; Gogos C
    J Med Virol; 2021 Jan; 93(1):56-58. PubMed ID: 32492200
    [No Abstract]   [Full Text] [Related]  

  • 10. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The shortcomings of tocilizumab in COVID-19.
    Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
    Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series.
    Yang SS; Boudjemai R; Lipes J
    J Cardiothorac Vasc Anesth; 2021 Jul; 35(7):2237-2239. PubMed ID: 33189533
    [No Abstract]   [Full Text] [Related]  

  • 13. Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID).
    Martínez-Urbistondo D; Costa Segovia R; Suárez Del Villar Carrero R; Risco Risco C; Villares Fernández P
    Clin Infect Dis; 2021 May; 72(9):1682-1683. PubMed ID: 32621739
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
    Russo G; Solimini A; Zuccalà P; Zingaropoli MA; Carraro A; Pasculli P; Perri V; Marocco R; Kertusha B; Del Borgo C; Del Giudice E; Fondaco L; Tieghi T; D'Agostino C; Oliva A; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
    PLoS One; 2021; 16(9):e0257376. PubMed ID: 34506608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.
    Koeckerling D; Barker J
    J Infect Dis; 2021 Sep; 224(6):934-937. PubMed ID: 34157110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Covid-19 cytokine storm by tocilizumab.
    Boretti A; Banik B
    J Med Virol; 2022 Mar; 94(3):823-828. PubMed ID: 34617604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Chen XJC; Altshuler D; Spiegler P; Brosnahan SB
    Ann Pharmacother; 2022 Apr; 56(4):507-508. PubMed ID: 34330173
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Bissell BD; Mefford B; Donaldson JC
    Ann Pharmacother; 2022 Apr; 56(4):505-506. PubMed ID: 34330160
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic.
    Morgan CE; Rimland CA; Bell GJ; Kim MK; Hedrick T; Marx A; Bramson B; Swygard H; Napravnik S; Schmitz JL; Carson SS; Fischer WA; Eron JJ; Gay CL; Parr JB
    Healthc (Amst); 2021 Dec; 9(4):100581. PubMed ID: 34626958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.